09-Feb-2012 - AMRI says the US FDA has no concerns about its sterile fill-finish facility in Burlington, Massachusetts and that the challenge now is to win back customers.
08-Feb-2012 - AMRI posted a Q4 loss on lower sales but predicts that contracting revenues and margins will increase in 2012 thanks to cost cutting measures and new contracts
07-Feb-2012 - Foreign currency effects left Indian contractor Jubilant Life Sciences with a third quarter loss despite record sales.
06-Feb-2012 - The desire to be an all-encompassing ‘one stop shop’ may be common to both contract research organisations (CRO) and contract manufacturing organisations (CMO), but that does not mean the terms CRO and CMO are synonymous according to industry leaders.
06-Feb-2012 - Outsourcing-pharma.com presents a round up the latest developments in the contract manufacturing sector – with news from Cambrex, Florida Biologix, SCM Pharma, Recipharm and OctoPlus.
02-Feb-2012 - A round-up of news in the contract manufacturing space, with developments at Foster Delivery Sciences, Excella, Catalent and RohnerChem.
02-Feb-2012 - Ipsen may take a writedown up to €180m after FDA action against its API CMO, Lonza, created supply uncertainties.
31-Jan-2012 - Ingredient maker Dishman Pharmaceuticals has confirmed that it may offload its Chinese API (active pharmaceutical ingredients) factory.
26-Jan-2012 - Outsourcing-Pharma presents a round-up of the latest headlines within the world of contract manufacturing. Catalent and Patheon have each launched oral dosage partnership news, whilst Frontage and AMPAC have received regulatory go-aheads.
25-Jan-2012 - Detailed market knowledge and an experienced CMO are still critical to successfully developing a biopharmaceutical or biosimilar according to Cobra Biologics.
25-Jan-2012 - Lonza has fired its CEO after a halving of net income prompted the board to find another leader for “the challenging years ahead”.
17-Jan-2012 - Swiss API maker Carbogen Amcis has bought French contract manufacturer Creapharm Parenterals to boost capabilities in early-phase high potency drug development.
12-Jan-2012 - Outsourcing to Indian CRAMS and bulk drug businesses will drive the country’s export growth, a credit rating agency said.
11-Jan-2012 - Amarin plans to add a fourth API maker to its supply chain as it prepares for a potential launch of its triglyceride lowering therapy, AMR101, in the US in 2012.
10-Jan-2012 - Sigma-Aldrich says it is a step closer to becoming a one-stop-shop for biopharmas in the drug discovery process after it inked a takeover agreement with biological testing firm BioReliance.
10-Jan-2012 - AMRI has begun reviewing its chemistry services operation in Hungary and says it may cut jobs and shift work to other facilities.
09-Jan-2012 - Toray Industries has acquired a stake in a Japanese CMO and ingredient supplier as part of its push into life sciences.
03-Jan-2012 - Manufacturing operations at Shasun Pharma’s plant in Cuddalore, Tamil Nadu are still suspended days after Southern India was battered by a cyclonic storm.
21-Dec-2011 - Lonza has expanded small molecule production capacity at its plant in Nansha, China to meet demand for clinical trial materials.
20-Dec-2011 - DSM Biologics will work with the Australian Institute for Bioengineering and Nanotechnology (AIBN) on the commercialisation of development-stage biologics projects.
08-Dec-2011 - Catalent says it will increase biologics capacity, joining the growing list of contractors investing in biodrug production.
05-Dec-2011 - The global contract manufacturing market may be showing signs of recovery but careful investment and focusing on core activities is still the most sensible approach according to Sweden-based CDMO Recipharm.
01-Dec-2011 - Biologics Modular is leasing its mobile production facilities to help clients make FDA regulated drugs without fixed plants.
30-Nov-2011 - Chemicals supplier Lonza will manufacture the API for a candidate Alzheimer’s disease drug being developed by Elan in an agreement announced yesterday.
29-Nov-2011 - An expanding CRAMS business and bulk drug strength makes Indian CMO Arch Pharmalabs’ IPO a solid investment, analysts report.